Mycofin Cream 10gm

Indications

Mycofree Cream is used to treat a variety of skin and nail fungal infections, including ringworm. It kills the fungus that causes the infection. Mycofree Cream is only for external use. It should be taken in the prescribed dose and duration.

Pharmacology

Through the inhibition of Squalene Epoxidase, Terbinafine, an Allylamine antifungal, suppresses the biosynthesis of Ergosterol (a fundamental component of fungi cell layer). This occurs in parasitic cell passage primarily because of the expanded film porousness that is blocked by the accumulation of high concentrations of squalene, not because of an inadequate ergosterol supply. Terbinafine hydrochloride may be fungicidal based on the sedate concentration and the contagious species test in vitro. However, it is unclear what clinical significance in vitro data has. Both in vitro and in clinical diseases, terbinafine has shown to be effective against the majority of strains of the target microorganisms, including Trichophyton Mentagrophyte and Trichophyton Rubrum.

Dosage & Administration

Terbinafine Cream: 

• Terbinafine cream should be applied once or twice daily.
• Cleanse and dry the affected areas thoroughly before applying the terbinafine cream.
• Apply the cream in a thin layer to the affected skin and the surrounding area and gently rub it in.
• In the case of intertriginous contaminations (submammary, interdigital, intergluteal, inguinal), a dressing strip may be used to secure the application, especially at night.

The following are the likely treatment durations:

• Tinea corporis and cruris: 1–2 weeks
• 1 week for tinea pedis
• 2 weeks for cutaneous candidiasis
• 2 weeks for pityriasis Versicolor
• The clinical side effects are usually relieved within a few days. Unpredictable use or premature discontinuation of treatment increases the risk of recurrence.
• If there are no signs of progress after two weeks, the decision should be confirmed.

Interaction

Terbinafine has been shown to inhibit the CYP450 2D6 isozyme in vivo studies. The following classes of medications are included in those that are transcendently metabolized by the CYP450 2D6 isozyme: tricyclic antidepressants, particular serotonin reuptake inhibitors, beta-blockers, antiarrhythmics lesson 1C (such as flecainide and propafenone), and monoamine oxidase inhibitors Sort B. Terbinafine co-administration should be done under careful observation and may call for a reduction in measurements of the 2D6-metabolized sedate.

Contraindications

People who are easily affected by terbinafine should not take tablets or creams containing terbinafine.

Side Effects

The adverse events listed include gastrointestinal issues (including loose stools, dyspepsia, and stomach pain), abnormal liver tests, rashes, urticaria, pruritus, and taste-disturbing influences. The unfavorable events were typically mild, transient, and did not result in cessation. According to the global experience with terbinafine use, adverse events include odd and symptomatic liver damage, and more rarely, cases of liver failure, some leading to death or liver transplant, real skin reactions, extreme neutropenia, thrombocytopenia, angioedema, and adversely susceptible responses (counting anaphylaxis). Other unfavorable reactions described include discomfort, exhaustion, spitting, arthralgia, myalgia, and hair loss.

Pregnancy & Lactation

Terbinafine Tablet: 

Pregnant women don't have any satisfying or well-controlled characteristics. It is advised against starting terbinafine while pregnant because animal reproduction theories do not always predict human reaction, which allows treatment of onychomycosis to be delayed until after pregnancy is over. Terbinafine is demonstrated in the breast drain of nursing mothers after verbal organization.

Terbinafine cream: 

Terbinafine therapy is not recommended for nursing mothers.
Animal ripeness and fetal poisoning quality suggest no negative effects. Terbinafine is not clinically used in pregnant women; therefore, unless potential benefits outweigh potential risks, terbinafine should not be managed. Because terbinafine is excreted in breast milk, breastfeeding mothers shouldn't receive terbinafine treatment.

Precautions & Warnings

Precautions:

Patients with chronic or active liver disease should not take terbinafine. A recent liver infection should be examined before recommending Terbinafine. Patients with and without pre-existing liver infections are both susceptible to hepatotoxicity. All patients who have recently taken terbinafine tablets are encouraged to undergo pretreatment serum transaminase (ALT and AST) tests.

Warnings: 

Terbinafine Tablet: 

• Rare cases of liver failure have occurred with the use of terbinafine tablets for the treatment of onychomycosis in people with and without preexisting liver disease, some leading to passing or liver transplant. The patients in the vast majority of liver cases related to terbinafine use had real basic systemic conditions and a dubious causal relationship with terbinafine. Patients with chronic or active liver disease may experience more serious hepatic events and/or their consequences. In the unlikely event that liver damage is demonstrated through biochemical analysis or other clinical evidence, terbinafine tablet therapy should be stopped. There have only been a few reports of true skin reactions (e.g., Stevens-Johnson Disorder and poisonous epidermal necrolysis). Terbinafine therapy needs to be stopped in the event that dynamic skin hasty develops.

Terbinafine Cream: 

• Terbinafine cream is essentially intended for external use. Avoiding making eye contact is advised.

Storage Conditions

Store in a cool and dry place, below 30°C, secure from light